5 Classic Cars That Will Have Massive Price Drops in the Summer of 2025

Classic car values are always shifting, but this summer, several iconic models are set for significant price drops. Economic pressures, changing buyer demographics, and high maintenance costs are driving down demand for many pre-1980s classics.
Read Next:
Find Out:
Lauren Fix, automotive expert at Car Coach Reports, explained that younger collectors are prioritizing modern classics from the 1980s and 1990s, leaving older, high-maintenance cars behind.
Inflation and uncertain consumer confidence are also making buyers more selective, especially as restoration expenses continue to climb. A 2024 WCShipping report, citing Hagerty and Classic Valuer data, found nearly half of classic car models lost 10-20% in value.
Here are five classic cars that are expected to see the steepest price declines in the summer of 2025, along with the reasons behind these changes.
The Ferrari 308 and 328, once icons of 1980s style and television fame, are now facing a market correction. Collectors are shifting their attention to rarer Ferraris or moving up to 1990s models like the F355, leaving the 308 and 328 with fewer interested buyers. Classic Cars Magazine notes that oversupply and high maintenance costs are pushing prices down, especially for mid-tier and driver-quality examples.
Fix expects the average 308 prices to drop from $60,000-$100,000 to $45,000-$75,000, with non-concours cars seeing the steepest declines. For enthusiasts, this summer could bring some of the best deals on these classic Ferraris in years, especially as sellers become more motivated to move inventory.
The Aston Martin DB4, DB5 and DB6 have long been seen as the pinnacle of British automotive luxury, especially the DB5 with its James Bond legacy. However, demand for these high-maintenance, high-cost vehicles is fading as younger collectors look to more modern, affordable classics. According to auto mechanic and JustAnswer expert Chris Pyle, non-American classics normally see price drops because they are less looked at by potential buyers.
The DB5's allure has softened, and the market is now saturated with restored examples, pushing prices down. As a result, expect to see notable price drops for all but the rarest, concours-quality cars. For buyers, this summer could be the best chance in years to own a legendary Aston Martin at a relative bargain.
The Chevrolet Corvette C3, a favorite among American muscle car fans, is experiencing softening demand and falling prices in 2025. Oversupply of lower-quality examples and shifting interest toward newer C4 and C5 models, which offer better performance and value, are contributing to the decline. Hagerty's auction data shows that muscle cars like the C3 are trailing in appreciation compared to modern classics, and economic uncertainty is making buyers more cautious.
According to Fix, non-Stingray or high-mileage C3s are expected to drop 10-20 percent in value, with average prices falling from $20,000-$30,000 to $15,000-$25,000. For those looking for a classic American sports car, this summer could be an ideal time to buy a C3 at a discount.
The Jaguar E-Type, once hailed as one of the most beautiful cars ever made, is now facing reduced demand and falling prices. Fix says less desirable Series II and III E-Types, especially coupes and less pristine convertibles, could decrease 15-20% in price.
Basically, high maintenance costs and a market flooded with restored examples are making it harder for sellers to command premium prices. Jaguar's rebrand and shift toward electric vehicles have also dampened enthusiasm for its classic models, especially among younger buyers, according to Topgear by BBC. For collectors, this summer could offer the rare chance to acquire an E-Type at a price not seen in years.
Air-cooled Porsche 911s have long been collector favorites, but the market is cooling for certain models in 2025. Hagerty reports that economic developments and changing consumer tastes are affecting older, non-iconic air-cooled Porsche 911 prices, especially as demand rises for water-cooled 911s. Maintenance costs and a saturated market are adding pressure, especially for high-mileage or less rare examples.
Fix expects base or driver-quality air-cooled 911s to drop 10-15 percent, with prices falling from $40,000-$70,000 to $35,000-$60,000. For buyers, this summer could be the right moment to finally own a classic Porsche at a more accessible price point.
More From GOBankingRates
3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025
6 Popular SUVs That Aren't Worth the Cost -- and 6 Affordable Alternatives
How Much Money Is Needed To Be Considered Middle Class in Your State?
This article originally appeared on GOBankingRates.com: 5 Classic Cars That Will Have Massive Price Drops in the Summer of 2025

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Associated Press

20 minutes ago

• Associated Press

Hall of Famer Dale Earnhardt Jr. wins NASCAR national series debut as crew chief at Pocono

LONG POND, Pa. (AP) — Dale Earnhardt Jr. might already be NASCAR's most popular crew chief. He's certainly an undefeated one. Pressed into unexpected service, Earnhardt called the shots for 18-year-old prospect Connor Zilisch in the No. 88 Chevrolet and they landed in victory lane Saturday in the second-tier Xfinity Series race at Pocono Raceway. 'We had a lot of things going our way,' Earnhardt said. Earnhardt — who won NASCAR's most-popular driver award 15 times — made a pit stop from his day job as team owner at JR Motorsports with normal crew chief Mardy Lindley suspended one race because of a lug nut infraction this month at Nashville. Aside from his duties as team owner, Earnhardt also was at Pocono for his role on the Prime broadcast for the NASCAR Cup Series race Sunday. 'Lot of fun for me today,' Earnhardt said. 'I missed the thrill of competition. I love broadcast, don't get me wrong. But nothing compares to driving or just being part of the team. Being an owner doesn't really deliver like this. This is a lot of fun.' Earnhardt had his wife and two young daughters in tow with him as he made the celebratory walk to victory lane. Oldest daughter Isla Rose clutched the checkered flag while youngest Nicole Lorraine soaked in the scene from her dad's arms. The win continued a banner season for the NASCAR Hall of Fame driver — who swept two races at Pocono as a driver in 2014 — after JR Motorsports and reigning Xfinity Series champion Justin Allgaier qualified for the season-opening Daytona 500 and secured their Cup Series debut. Earnhardt won two Daytona 500s, in 2004 and 2014, and 26 races overall. His side hustle Saturday was made a bit easier with Zilisch behind the wheel. Zilisch, who turns 19 in July, raced to his second Xfinity victory of the season and third of his young career. He won his Xfinity debut last year at Watkins Glen International. Earnhardt even pitched in during the race and tossed tires over the wall during pit stops. Zilisch took the win down to the wire and finally passed Jesse Love with five laps left in the race. Love finished second. 'Dale Junior, not too bad on the box,' Zilisch said. 'Pretty cool to have him up there. Getting him a 1-for-1 win as crew chief is pretty awesome.' ___ AP auto racing:

Yahoo

25 minutes ago

• Yahoo

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press

28 minutes ago

• Associated Press

American Rebel Light Virginia NHRA Nationals Pairings

Saturday At Virginia Motorsports Park Dinwiddie, Va. Sunday's Pairings Top Fuel 1. Brittany Force, 3.839 seconds, 327.98 mph vs. 14. Tony Stewart, 8.979, 79.59; 2. Clay Millican, 3.864, 324.90 vs. 13. Smax Smith, 5.979, 107.70; 3. Steve Torrence, 3.877, 324.28 vs. 12. Josh Hart, 5.956, 108.41; 4. Shawn Reed, 3.885, 323.74 vs. 11. Dan Mercier, 4.284, 206.07; 5. Shawn Langdon, 3.891, 325.45 vs. 10. Cameron Ferre, 4.070, 287.60; 6. Doug Foley, 3.896, 310.91 vs. 9. Justin Ashley, 3.950, 305.63; 7. Doug Kalitta, 3.905, 327.43 vs. 8. Antron Brown, 3.944, 312.50. Funny Car 1. Jack Beckman, Chevy Camaro, 3.988, 320.51 vs. 16. Jim Campbell, Ford Mustang, 9.864, 74.26; 2. Austin Prock, Camaro, 4.004, 321.73 vs. 15. Cruz Pedregon, Dodge Charger, 5.867, 118.17; 3. J.R. Todd, Toyota GR Supra, 4.018, 320.05 vs. 14. Buddy Hull, Charger, 5.184, 144.64; 4. Daniel Wilkerson, Mustang, 4.022, 320.74 vs. 13. Dave Richards, Mustang, 4.267, 291.45; 5. Ron Capps, GR Supra, 4.028, 320.81 vs. 12. Chad Green, Mustang, 4.081, 314.17; 6. Matt Hagan, Charger, 4.039, 319.07 vs. 11. Hunter Green, Charger, 4.080, 314.46; 7. Bob Tasca III, Mustang, 4.047, 319.75 vs. 10. Spencer Hyde, Mustang, 4.069, 306.46; 8. Alexis DeJoria, Charger, 4.050, 317.79 vs. 9. Paul Lee, Charger, 4.052, 307.93. Pro Stock Motorcycle 1. Brayden Davis, Suzuki, 6.757, 198.85 vs. 16. Marc Ingwersen, EBR, 6.924, 194.72; 2. Matt Smith, Buell, 6.768, 201.43 vs. 15. Chase Van Sant, Suzuki, 6.907, 196.44; 3. John Hall, Beull, 6.787, 199.97 vs. 14. Chris Bostick, Suzuki, 6.898, 196.50; 4. Gaige Herrera, Suzuki, 6.793, 199.49 vs. 13. Ron Tornow, Victory, 6.898, 198.55; 5. Steve Johnson, Suzuki, 6.801, 197.54 vs. 12. Kelly Clontz, Suzuki, 6.897, 197.62; 6. Richard Gadson, Suzuki, 6.809, 199.73 vs. 11. Hector Arana Jr, EBR, 6.877, 198.09; 7. Angie Smith, Buell, 6.813, 199.70 vs. 10. Dystany Spurlock, Buell, 6.870, 194.66; 8. Ryan Oehler, EBR, 6.848, 198.44 vs. 9. Jianna Evaristo, Buell, 6.863, 199.29. Did Not Qualify: 17. Brandon Litten, 6.960, 192.58. _____